Ionis Pharma

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics segments. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The Akcea Therapeutics segment develops and commercializes drugs for cardiometabolic diseases. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli, and Brett P. Monia in 1989 and is headquartered in Carlsbad, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Ionis Pharma excels in Q4, eyes revenue growth and strategic expansion

Ionis Pharma's Q4 2022 performance reflects strong revenue growth, pipeline advancements, and strategic positioning for future success.
The company's focus on commercialization, R&D innovation, and financial discipline underscores its resilience and growth potential in the biopharmaceutical industry.
While facing challenges in operational costs and market dynamics, Ionis Pharma remains well-positioned to leverage opportunities in genetic medicines and revenue diversification.

Ionis Pharma reports strong Q1 earnings and outlines growth plans

Ionis Pharma's Q1 performance solid with revenue growth and strong cash position
Company's strengths lie in FDA approvals, positive study data, and pipeline progress
Challenges include rising expenses, competitive landscape, and pricing strategies
Opportunities seen in PV market, HAE program, and growth prospects in coming years

Ionis Pharma reports strong Q2 performance and prepares for launches

Ionis Pharma's Q2 2023 earnings call highlighted strong performance, with revenue growth, key milestones in pipeline advancements, and a solid financial position.
The company faces challenges in study readout timing, competitive landscape changes, and market competition but has opportunities for growth through successful enrollment and product launches.
Key strengths include successful collaborations, encouraging interim results for SPINRAZA, and preparations for upcoming product launches, positioning Ionis Pharma for future success.
Overall, Ionis Pharma remains focused on advancing its pipeline, meeting financial guidance, and leveraging opportunities for growth in the biopharmaceutical market.

Ionis Pharma reports strong Q3 performance and neurology pipeline advancements

Ionis Pharma's Q3 earnings call highlighted strong performance, strategic successes, and advancements in the neurology pipeline.
The company faces challenges in a competitive landscape but has strengths in partnerships, innovation, and pricing strategies.
Opportunities lie in upcoming data releases, potential treatment benefits, and market differentiation strategies.
Overall, Ionis Pharma remains focused on delivering value to patients and investors through its innovative therapeutics.

Ionis Pharma reports robust 2023 results and eyes growth opportunities

Ionis Pharma's strong financial performance in 2023 and projected revenue for 2024 reflect a promising outlook for the company's growth and commercialization efforts.
While facing challenges in patient eligibility and treatment optimization, Ionis Pharma's focus on pipeline advancement and strategic investments positions it well for future success.
The company's emphasis on neurological disease platforms, upcoming data readouts, and collaborations present significant opportunities for expansion and innovation.

Ionis Pharma reports robust Q1 performance and advances key treatments

Ionis Pharma's Q1 2024 performance reflects strong revenue growth and progress in key pipeline programs, positioning the company for future success and sustained positive cash flow.
With a focus on strategic investments, innovative treatments, and upcoming data presentations, Ionis demonstrates a commitment to driving growth and addressing unmet medical needs.
While facing challenges in managing expenses and securing regulatory approvals, Ionis Pharma remains well-positioned to capitalize on market opportunities and partnerships for continued development and commercial success.

Ionis Pharma reports solid Q2 earnings, eyes growth through innovation

Ionis Pharma's Q2 performance reflects steady revenue growth and positive feedback on recent launches and ongoing trials.
The company's strengths lie in its innovative therapies, strong clinical profile, and strategic focus on expanding the product portfolio.
Challenges include sustaining momentum in competitive markets and ensuring successful commercialization of upcoming products.
Opportunities exist in market expansion, new patient segments, partnerships for pipeline growth, and investments in next-gen technologies.

Ionis Pharma reports strong pipeline progress and commercial success

Ionis Pharma's Q3 earnings call highlighted positive pipeline developments, successful product launches, and sustained investment for growth.
While facing challenges in competitive positioning and data availability, Ionis Pharma remains focused on leveraging opportunities in patient engagement and market expansion.
Overall, Ionis Pharma's performance reflects a promising outlook with strong potential for future growth and market impact.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core segment. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli, and Brett P. Monia on January 10, 1989 and is headquartered in Carlsbad, CA.

Ionis (IONS) incurs a narrower-than-expected fourth-quarter loss. Sales beat estimates.

Ionis (IONS) Q4 Loss Narrower Than Expected, Sales Surge Y/Y

Ionis Pharmaceuticals, Inc. (IONS) Q4 2023 Earnings Call Transcript

The headline numbers for Ionis Pharmaceuticals (IONS) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Ionis Pharmaceuticals (IONS) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Ionis Pharmaceuticals (IONS) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.78. This compares to loss of $0.37 per share a year ago.

Ionis Pharmaceuticals (IONS) Reports Q4 Loss, Tops Revenue Estimates

WAINUA™  approved with launch underway; on track for EU and Canada approval decisions this year Positive Phase 3 olezarsen and donidalorsen data, preparing regulatory submissions for FCS and HAE, respectively Olezarsen granted Breakthough Therapy designation by the FDA for FCS Ionis provides full year 2024 financial guidance CARLSBAD, Calif. , Feb. 21, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the "Company"), today reported financial results for the fourth quarter and full year ended December 31, 2023.

Ionis reports fourth quarter and full year 2023 financial results

FDA grants orphan drug status to Ionis' (IONS) olezarsen for treating familial chylomicronemia syndrome (FCS). An NDA for olezarsen is expected to be filed this year.

Ionis' (IONS) Olezarsen Gets FDA's Orphan Tag for Rare Disease

Evaluate the expected performance of Ionis Pharmaceuticals (IONS) for the quarter ended December 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Ionis Pharmaceuticals (IONS) Q4 Earnings Preview: What You Should Know Beyond the Headline Estimates

CARLSBAD, Calif. , Feb. 15, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to the investigational medicine olezarsen for the treatment of familial chylomicronemia syndrome (FCS), a rare, genetic disease characterized by extremely elevated triglyceride levels and recurrent acute pancreatitis (AP).

Olezarsen receives Orphan Drug designation from U.S. FDA for familial chylomicronemia syndrome

Ionis Pharmaceuticals (IONS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

The FDA bestows a Fast Track designation to Ionis (IONS) and partner AstraZeneca's (AZN) eplontersen for treating adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM).

Ionis' (IONS) Eplontersen Gets Fast Track Tag for New Indication

CARLSBAD, Calif. , Feb. 8, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Ionis and AstraZeneca's eplontersen, an investigational therapy for the treatment of transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) in adults.

Eplontersen granted U.S. FDA Fast Track designation for patients with transthyretin-mediated amyloid cardiomyopathy

Webcast scheduled for Wednesday, February 21 at 11:30 a.m. Eastern Time CARLSBAD, Calif.

Ionis to hold fourth quarter and full year 2023 financial results webcast

MARSEILLE, France--(BUSINESS WIRE)--Vect-Horus announced it has entered into a global license agreement with Ionis Pharmaceuticals, Inc. (Nasdaq: IONS).

Vect-Horus Enters Exclusive License Agreement with Ionis Pharmaceuticals to Advance Systemic Delivery of RNA-Targeted Medicines for Neurological Diseases

Ionis (IONS) reports positive phase III study results, which show that treatment with donidalorsen achieved a statistically significant reduction in HAE attacks.

Ionis' (IONS) Donidalorsen Meets Late-Stage HAE Study Goal

Ionis Pharmaceuticals said on Monday its therapy for the treatment of a rare genetic disease met the main goal in a late-stage trial.

Ionis Pharma's genetic disease drug succeeds in late-stage study

Donidalorsen met the primary endpoint with a statistically significant reduction in the rate of HAE attacks in patients treated every 4 weeks or patients treated every 8 weeks  Donidalorsen demonstrated a favorable safety and tolerability profile Ionis is preparing to submit a New Drug Application with U.S. FDA Data to be presented at an upcoming medical congress CARLSBAD, Calif. , Jan. 22, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced positive topline results for the Phase 3 OASIS-HAE study of donidalorsen in people with hereditary angioedema (HAE).

Ionis announces positive topline results from Phase 3 OASIS-HAE study of investigational donidalorsen in patients with hereditary angioedema

– Numerous value-driving commercial, regulatory and pipeline milestones anticipated – CARLSBAD, Calif. , Jan. 8, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced highlights from the Company's 2023 achievements and previewed a number of important milestones expected in 2024.

Ionis poised for continued momentum in 2024 with product launches and key advances in robust pipeline of investigational medicines for serious diseases

Iovance Biotherapeutics

Intra-Cellular Therapies

Madrigal Pharmaceuticals

Verve Therapeutics

SPDR S&P Biotech ETF

The biotech sector is finishing 2023 on a high after a difficult couple of years, buoyed by Big Pharma M&A activity. The SPDR® S&P Biotech ETF has been soaring as a result of the M&A spree. Despite a challenging year, there have been some winners in the biotech sector - I have been fortunate to share a few successful tips with Seeking Alpha readers.

3 Biotech Bull Cases To Consider In 2024 - And 2 Wildcard Recommendations

Taiwan Semiconductor Manufacturing

UnitedHealth Group

Heading into 2024, the future of the U.S. economy remains uncertain, with conflicting predictions about the possibility of a recession. While some experts anticipate a soft landing, others predict a mild recession starting in the second quarter.

3 Stocks to Buy Now Before They Become Tomorrow's Trillion-Dollar Companies

FDA approves Ionis (IONS) and partner AstraZeneca's (AZN) Wainua for treating ATTRv-PN. Ionis stock rises on this important milestone.

Ionis (IONS), AstraZeneca's Eplontersen Receives FDA Nod

AstraZeneca

Ionis Pharmaceuticals IONS, +1.61% and AstraZeneca's AZN, +0.79% Wainua has been approved by the U.S. Food and Drug Administration for treating a symptom of a rare genetic disease.

Ionis Pharmaceuticals, AstraZeneca get FDA approval for rare genetic disease treatment

U.S. FDA approval based on Phase 3 NEURO-TTRansform results showing WAINUA demonstrated consistent and sustained benefit halting neuropathy disease progression and improving neuropathy impairment and quality of life Additional regulatory reviews for WAINUA underway in rest of world WAINUA will be available in the U.S. in January 2024 CARLSBAD, Calif. , Dec. 21, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has approved Ionis and AstraZeneca's WAINUA™ (eplontersen) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults, commonly referred to as hATTR-PN or ATTRv-PN.

WAINUA™ (eplontersen) granted regulatory approval in the U.S. for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis

The U.S. Food and Drug Administration (FDA) on Thursday approved Ionis Pharmaceuticals and partner AstraZeneca's drug to treat nerve damage caused by a life-shortening rare disease.

US FDA approves Ionis-AstraZeneca's nerve disease drug

CARLSBAD, Calif. , Dec. 20, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Brett P.

Ionis to present at 42nd Annual J.P. Morgan Healthcare Conference

Per the agreement, Ionis (IONS) will be responsible for the clinical development of the HAE drug. Otsuka will be responsible for all regulatory filings and commercialization activities in Europe.

News for Ionis Pharma Stock (IONS)